The key point is not that one pipeline asset is better than another
Semaglutide (Wegovy, Ozempic) received FDA approval for chronic weight management in 2021, followed by tirzepatide (Zepbound) in 2023, both demonstrating substantial weight loss in clinical trials
This is when semaglutide's effect on gastric motilitythe speed at which food moves through your stomachreaches its height
Novo Nordisk sets the list price for Wegovy at over $1,300/month, reflecting their investment in clinical trials, manufacturing, and regulatory approval
The medication is used off-label for weight management
What the Company Describes About User Experiences The company references user-reported experiences that include changes in appetite, energy levels, and weight-related outcomes